Fmr LLC lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,353 shares of the company’s stock after purchasing an additional 934 shares during the quarter. Fmr LLC’s holdings in IDEXX Laboratories were worth $6,030,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. WMS Partners LLC grew its stake in shares of IDEXX Laboratories by 0.3% during the 2nd quarter. WMS Partners LLC now owns 1,583 shares of the company’s stock worth $256,000 after purchasing an additional 4 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in shares of IDEXX Laboratories by 0.3% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,547 shares of the company’s stock worth $1,057,000 after purchasing an additional 19 shares during the period. CAPROCK Group Inc. grew its stake in shares of IDEXX Laboratories by 2.2% during the 2nd quarter. CAPROCK Group Inc. now owns 1,830 shares of the company’s stock worth $295,000 after purchasing an additional 40 shares during the period. Strs Ohio grew its stake in shares of IDEXX Laboratories by 0.7% during the 2nd quarter. Strs Ohio now owns 5,929 shares of the company’s stock worth $957,000 after purchasing an additional 41 shares during the period. Finally, Synovus Financial Corp grew its stake in shares of IDEXX Laboratories by 2.8% during the 2nd quarter. Synovus Financial Corp now owns 2,249 shares of the company’s stock worth $361,000 after purchasing an additional 61 shares during the period. 87.63% of the stock is currently owned by institutional investors and hedge funds.

In related news, CEO Jonathan W. Ayers sold 18,000 shares of the company’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $154.91, for a total transaction of $2,788,380.00. Following the transaction, the chief executive officer now owns 1,043,034 shares of the company’s stock, valued at $161,576,396.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Rebecca M. Henderson sold 5,156 shares of the company’s stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $153.29, for a total value of $790,363.24. Following the transaction, the director now directly owns 17,274 shares in the company, valued at approximately $2,647,931.46. The disclosure for this sale can be found here. Insiders have sold 151,734 shares of company stock worth $23,436,626 in the last ninety days. 2.77% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Fmr LLC Has $6.03 Million Stake in IDEXX Laboratories, Inc. (IDXX)” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.watchlistnews.com/fmr-llc-has-6-03-million-stake-in-idexx-laboratories-inc-idxx/1674933.html.

A number of research analysts have recently issued reports on the company. Canaccord Genuity reiterated a “buy” rating and set a $180.00 target price on shares of IDEXX Laboratories in a research report on Friday, October 6th. Bank of America Corporation upgraded IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 target price on the stock in a research report on Wednesday, August 23rd. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $186.00 target price on the stock in a research report on Wednesday, July 19th. Stifel Nicolaus reiterated a “buy” rating and set a $185.00 target price on shares of IDEXX Laboratories in a research report on Wednesday, August 2nd. Finally, CL King upgraded IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 target price on the stock in a research report on Friday, July 28th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. IDEXX Laboratories presently has an average rating of “Hold” and a consensus price target of $173.67.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The firm had revenue of $492.00 million for the quarter, compared to analyst estimates of $492.94 million. During the same quarter in the prior year, the company posted $0.62 earnings per share. IDEXX Laboratories’s quarterly revenue was up 9.7% on a year-over-year basis.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.